Literature DB >> 23677658

Late-onset Pompe's disease.

James W Teener1.   

Abstract

Glycogen storage disease type II, also known as Pompe's disease or acid maltase deficiency, is caused by a deficiency in acid α-glucosidase. Severe enzyme deficiency results in infantile Pompe's disease with multiorgan involvement; a partial deficiency produces a less severe phenotype mainly consisting of a myopathy, with a later age of onset. Treatment is now available with intravenous infusion of recombinant acid α-glucosidase. Such treatment results in marked improvement in patients with infantile Pompe's disease, and modest improvement or stabilization in patients with late-onset Pompe's disease. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23677658     DOI: 10.1055/s-0033-1334469

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  4 in total

1.  Multiple, Successful Pregnancies in Pompe Disease.

Authors:  Ursula Plöckinger; Nikolaus Tiling; Lenka Bosanska; Bettina Temmesfeld-Wollbrueck; Kerstin Irlbacher; Viktor Mezger; Gabriele Gossing
Journal:  JIMD Rep       Date:  2015-11-17

2.  Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Authors:  Elisa Masat; Pascal Laforêt; Marie De Antonio; Guillaume Corre; Barbara Perniconi; Nadjib Taouagh; Kuberaka Mariampillai; Damien Amelin; Wladimir Mauhin; Jean-Yves Hogrel; Catherine Caillaud; Giuseppe Ronzitti; Francesco Puzzo; Klaudia Kuranda; Pasqualina Colella; Roberto Mallone; Olivier Benveniste; Federico Mingozzi
Journal:  Sci Rep       Date:  2016-11-04       Impact factor: 4.379

3.  Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Authors:  W N Löscher; M Huemer; T M Stulnig; P Simschitz; S Iglseder; C Eggers; H Moser; D Möslinger; M Freilinger; F Lagler; S Grinzinger; M Reichhardt; R E Bittner; W M Schmidt; U Lex; M Brunner-Krainz; S Quasthoff; J V Wanschitz
Journal:  J Neurol       Date:  2017-11-27       Impact factor: 4.849

4.  2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.

Authors:  U Plöckinger; V Prasad; A Ziagaki; N Tiling; A Poellinger
Journal:  Hum Genomics       Date:  2018-03-09       Impact factor: 4.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.